A detailed history of Park Place Capital Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Park Place Capital Corp holds 16 shares of NBIX stock, worth $2,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 16 -0.0%
Holding current value
$2,008
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

SELL
$89.53 - $104.87 $63,118 - $73,933
-705 Reduced 97.78%
16 $1,000
Q1 2023

May 02, 2023

BUY
$94.11 - $123.02 $846 - $1,107
9 Added 1.26%
721 $72,000
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $75,984 - $90,466
712 New
712 $85,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Park Place Capital Corp Portfolio

Follow Park Place Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Place Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Park Place Capital Corp with notifications on news.